1. Introduction
Viruses are the most opportunistic pathogens, since they extensively use host cell components for their replication. Among the various host factors usurped by viruses, proteins involved in RNA processing pathways are frequently used to regulate their own replication and to affect host protein expression (Lai, 1998). Over the years, the study of viral replication led to discoveries on how cellular RNA processing pathways are complex and how each step is crucial and extremely regulated. In addition to provide a better understanding of viral pathogenesis, investigation of viruses continue to be used as tools to understand the normal cellular RNA processing pathways and to identify new actors or new functions of known components.
The hepatitis
2. The hepatitis delta virus
HDV is a defective RNA virus that requires the hepatitis B virus (HBV) envelope proteins for encapsidation and dissemination (Rizzetto et al., 1977). Co- and super-infection of HBV carriers by HDV causes acute exacerbation of the disease and subsequent chronic hepatitis. People with HDV superinfection have a much greater risk of developing fulminant hepatitis, hepatocellular carcinoma, cirrhosis, and liver failure than people infected with HBV alone (Fattovich et al., 2004; Su et al., 2006; Taylor, 2006; Romeo et al., 2009).
As stated above, HDV is the smallest known human RNA pathogen. It consists of a circular negative single-stranded RNA of about 1,680 nucleotides. This RNA can fold on itself using 74% intra-molecular base-pairing to form an unbranched, rod-like structure that can be divided into two domains (Fig. 1; reviewed by (Chen et al., 1986; Lai, 2005; Taylor, 2006, 2009; Tseng & Lai, 2009)). The left-terminal domain (~360 nt) includes both genomic and antigenomic self-cleaving motifs (i.e.
HDAgs are RNA binding proteins that associate with HDV genomic RNA to form ribonucleoprotein (RNP) complexes in the HDV-containing HBV virion and in transfected cells (Chang et al., 1988; Niranjanakumari et al., 2002; Chang et al., 2008). This binding is likely facilitated by the rod-like structure adopted by the HDV RNA genome. In addition, HDAg-S can function as an RNA chaperone and modulate the ribozyme activity of HDV RNA (Wang et al., 2003), and is proposed to shuttle HDV RNA to the nucleus for replication, to the cytosol for packaging and export (Ryu et al., 1993; Lai, 2005; Taylor, 2006), and to modulate both HDV transcription and replication (Yamaguchi et al., 2001). Both HDAgs are post-translationally modified (i.e. serine and threonine phosphorylation (Chang et al., 1988; Mu et al., 1999; Mu et al., 2001), arginine methylation (Li et al., 2004), lysine acetylation (Mu et al., 2004), and cysteine farnesylation (Glenn et al., 1992; Otto & Casey, 1996)). These modifications regulate intermolecular interactions affecting subcellular localization of HDAgs and HDV RNA synthesis (Mu et al., 2001; Li et al., 2004; Mu et al., 2004).
Replication of HDV RNA is considered to take place in the nucleus of the infected cells using a symmetrical rolling cycle mechanism (Fig. 2; Taylor, 2009). Replication of the infectious circular RNA monomer (which is assigned genomic polarity by convention and accumulates to a greater intracellular abundance than the antigenomic species) produces linear, multimeric strands which are subsequently cleaved by endogenous ribozymes and ligated, yielding antigenomic circular RNA monomers (~30,000 copies). Using the latter RNAs as templates, the same three steps are repeated to generate the genomic RNA progeny (~300,000 copies). A third RNA also accumulates during replication, which corresponds to the unique HDV mRNA (~600 copies).
3. The pathogenesis of hepatitis delta virus
Despite its apparent simplicity, HDV causes one of the most serious and rapidly progressive viral hepatitis. It provokes severe acute and chronic liver diseases, and it is associated with the development of hepatocellular carcinoma (Fattovich et al., 2004; Su et al., 2006; Taylor, 2006; Romeo et al., 2009). Interestingly, it was found that HBV replication is repressed in the presence of HDV (Krogsgaard et al., 1987; Farci et al., 1988), suggesting that the induced liver damage is likely caused by HDV replication rather than by HBV.
Since the genome of HDV can replicate in animal cells independently of HBV, many experimental systems using transfection of mammalian cells have examined the impact of the accumulation of HDAg and/or HDV RNA on the phenotype of cells in culture. It has been suggested that expression of HDAg-S or HDAg-L in mammalian cells might cause HDV pathogenesis (Cole et al., 1991; Cole et al., 1993). In contrast, some reports have shown that HDV RNA replication, rather than expression of the HDAgs, might be responsible for the cytopathic effects (Wang et al., 2001). At low concentrations of HDAg-S and without HDAg-L, low levels of HDV genome replication was reported to be able to proceed for at least 2 years without any deleterious effects on the host cell (Chang et al., 2005). When higher level of HDV RNA was induced, cell-cycle arrest in G1/G0 was observed followed by cell death (Chang et al., 2005). Using such systems, experiments have shown that when HDAg and/or HDV RNA are over-expressed, host proteins involved in regulation of cell metabolism and energy pathways, nucleic acid and protein metabolism, transport, signal transduction, apoptosis, and cell growth and maintenance are differentially produced (Mota et al., 2008; Mota et al., 2009). During viral replication, interaction of host factors with both HDAg and the HDV RNA genome might thus affect normal cellular activities.
4. Hijacking of cellular RNA processing machinery by HDV
Because HDV has an extremely limited protein coding capacity, it is completely dependent on its host cell for its replication. HDV has to interact and divert several proteins during its life cycle, including those in the nucleus involved in both viral replication and transcription and those in the cytoplasm that are required for the production of HDAgs. The high accumulation of HDV RNA in infected cells (Chen et al., 1986) suggests that the interaction of HDV RNA with host factors might interfere with several of the normal cellular functions, thereby eliciting the virus’ pathogenic effect. Over the last few years, studies have investigated cellular proteins that might interact with either HDAgs or HDV RNA. Several of these proteins are involved in RNA processing, including RNA polymerase subunits, heterogeneous ribonucleoproteins (hnRNPs), RNA helicases, RNA-binding proteins, and both transcription and splicing factors (for a review, see (Greco-Stewart & Pelchat, 2010)). However, the physiological significance of the interaction of most of these proteins remains enigmatic and the identification of additional host factors involved in viral replication is still required to gain a better understanding of both HDV replication and the associated pathogenicity.
4.1. HDV uses host RNA polymerase(s) for both its replication and transcription.
Because HDV does not encode its own replicase, host DNA-dependent RNA polymerases (RNAPs) are considered to be involved in the replication and transcription of HDV RNAs. Several approaches have been used to identify the host RNAP(s) involved in HDV replication/transcription and to study how this redirection from DNA to RNA templates occurs. However, it is largely unknown how the RNA-dependent RNA synthesis of HDV proceeds and there is still controversy on the identity of the RNAP(s) involved in HDV replication.
Many studies using cultured cells and cell extracts have provided evidence of the involvement of RNAP II in HDV replication based on the sensitivity of the accumulation of HDV mRNA and processed unit-length genomic HDV RNAs to low levels of α-amanitin, a mycotoxin that inhibits DNA-dependent RNA synthesis by RNAP II (MacNaughton et al., 1991; Fu & Taylor, 1993; Filipovska & Konarska, 2000; Moraleda & Taylor, 2001; Chang et al., 2008). These results were substantiated by experiments using cells containing an α-amanitin-resistant allele of the largest subunit of RNAP II, which partially relieved transcription inhibition by α-aminitin (Filipovska & Konarska, 2000). RNAP II is furthermore speculated to be involved in the transcription of the HDAg mRNA because,
Synthesis of complementary strands was possible in transcription assays using nuclear extract (NE) from HeLa cells and RNA derived from the left terminal stem-loop domain of antigenomic HDV RNA (Filipovska & Konarska, 2000). Accumulation of this RNA product was highly sensitive to α-amanitin. This sensitivity was partially abrogated in experiments conducted in NE from cells containing an α-amanitin-resistant allele of the largest subunit of RNAP II, suggesting the involvement of RNAP II in this reaction. Interestingly, the transcription did not proceed by
Recently, RNAP II was reported to interact with HDV-derived RNAs at sites located within the terminal stem-loop domains of both polarities of HDV RNA (Greco-Stewart et al., 2007; Abrahem & Pelchat, 2008; Chang et al., 2008). Mutagenesis near these tips of the rod affects both HDV accumulation in cells and RNAP II binding
In contrast to the genomic RNA and HDAg mRNA, the synthesis of the antigenomic species has been shown to be resistant to higher doses of α-amanitin and to take place in the nucleolus, suggesting the involvement of another yet unknown RNAP in the life cycle of HDV (Modahl et al., 2000; Macnaughton et al., 2002; Li et al., 2006). It has been hypothesized that RNAP I or an RNAP I-like polymerase might be involved in HDV replication, because
4.2. Interaction of host proteins with HDAgs.
Several RNA helicases were found to interact with HDAgs, including nucleolin, nucleophosmin, DDX1 and DHX15 (Lee et al., 1998; Huang et al., 2001; Cao et al., 2009). Nucleolin is a multifunctional nuclear phosphoprotein with both DNA/RNA helicase and ATPase activities, and is involved in several processes, including synthesis and maturation of the ribosome, cell proliferation and growth, nuclear trafficking, cytokinesis, nucleogenesis, transcriptional repression, replication, signal transduction, and chromosome remodelling (Tuteja & Tuteja, 1998). The nucleolin-binding domain of HDAgs is conserved among HDV variants, and it was shown that this domain is required for nucleolar targeting and accumulation of HDV RNA. Like Nucleolin, nucleophosmin is another multifunctional nuclear phosphoprotein that has been shown to interact with both HDAg-S and HDAg-L (Huang et al., 2001). This protein is involved in cell growth and proliferation, nuclear shuttling, and ribosome biogenesis. Nucleophosmin was reported to be upregulated in cells replicating HDV and to co-localize with HDAg in the nucleolus (Okuwaki, 2008). Both DDX1 and DHX15 are ATP-dependent RNA helicases involved in cellular processes such as alteration of RNA secondary structure during translation initiation, splicing, and both ribosome and spliceosome assembly (de la Cruz et al., 1999; Wen et al., 2008). Although the function of all these RNA helicases in HDV replication is unknown, their levels correlates with the amount of HDV RNA present in cells (Huang et al., 2001; Cao et al., 2009), suggesting that they might enhance HDV replication by affecting the localization of HDV RNPs. Alternatively, they might assist to the refolding of the HDV RNA genome during viral replication (Ghisolfi et al., 1992; Tuteja & Tuteja, 1998). However, it is possible that their interaction with HDAgs might be indirect since all the interactions were also observed in the absence of HDV replication (Hiscox, 2002; Cao et al., 2009; Han et al., 2009).
HDAg-S was also found to interact with many proteins capable of associating with the Argonaute (Ago) proteins, and suspected to be involved in miRNA-mediated silencing (Haussecker et al., 2008; Cao et al., 2009). Using a combined proteomic-RNAi screen, several RNA-binding proteins (IMP2, IMP3, RALY, RBM14, ILF2, and ILF3), the polyadenylate-binding protein 4 (BABPC4), and the putative RNA helicase MOV10 were found to be required for efficient HDV replication (Haussecker et al., 2008; Cao et al., 2009). Interestingly, HDV accumulation was found to be diminished only when Ago4 expression wass prevented, but not in the absence of Ago1-3 (Haussecker et al., 2008). Although the precise function of all these proteins for HDV is unclear, it was suggested that some uncharacterized downstream effectors in the microRNA (miRNA) interference pathway might remodel HDV RNA and facilitate HDV replication/transcription (Haussecker et al., 2008). It is also possible that during HDV replication, specific miRNA pathways might be deregulated.
4.3. Interaction of host proteins with the HDV RNA genome.
An essential host protein for the progression of HDV infection is the adenosine deaminase that acts on RNA (ADAR). This enzyme is involved in site-selective RNA editing, by changing specific adenosine residues to inosine (Fig. 1; Casey et al., 1992; Casey & Gerin, 1995). The small isoform of adenosine deaminase acting on RNA (ADAR-1) performs the post-transcriptional RNA editing of the HDV antigenome leading to the production of HDAg-L (Wong & Lazinski, 2002). Specifically, during HDV replication, the UAG amber termination codon of HDAg-S is converted to UIG on the antigenomic RNA genome. When genomic RNA is generated from the modified antigenome, inosine is read as guanine yielding a codon for tryptophan instead of a stop codon. This modification is retained in subsequent rounds of replication and results in translational readthrough which produces HDAg-L. HDAg-S was shown to inhibit this editing event (Polson et al., 1998), thus delaying HDAg-L production and regulating HDV life cycle. As stated above, HDV RNA accumulating at high levels was shown to be pathogenic to the cell (Chang et al., 2005). Thus, it is possible that during a typical HDV infection, HDV RNA-editing by ADAR-1, with the appearance of HDAg-L and the resulting down-regulation of viral RNA replication might have been selected to insure cell survival.
Recently, several approaches were used to identify additional host proteins that might be involved in HDV replication using HDV-derived RNA fragments as baits (Sikora et al., 2009). These studies led to the identification of SC35, ASF/SF2, the heterogeneous ribonucleoproteins L (hnRNP-L), the polypyrimidine tract-binding (PTB) protein-associated splicing factor (PSF), p54nrb, the glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the eukaryotic translation elongation factor 1 alpha 1 (eEF1A1). Due to their specific interactions with both polarities of HDV RNA (Sikora et al., 2009), it is possible that these RNA processing proteins could play a role in HDV RNA biology.
SC35, ASF/SF2 and hnRNP-L are abundant nuclear proteins playing important roles in pre-mRNA splicing and various RNA metabolism pathways (Hastings & Krainer, 2001). Both ASF/SF2 and hnRNP-L have also been shown to enhance cytoplasmic accumulation of an intronless mRNA (Liu & Mertz, 1995; Huang & Steitz, 2001). For example, hnRNP-L was reported to enhance cytoplasmic export of the herpes simplex virus thymidine kinase intronless mRNA by binding to the pre-mRNA processing enhancer (PPE; Liu & Mertz, 1995). Although SC35, ASF/SF2 and hnRNP-L have the ability to bind to the HDV RNA genome (Sikora et al., 2009), the functions of these proteins in the HDV life cycle is unknown. One possibility is that they might have a role in HDV RNA cellular localization, since HDV RNA is intronless. Furthermore, because hnRNP-L can also interact with HDAg-S (Cao et al., 2009), a complex of these two proteins might modulate HDV RNA shuttling in the cell. HDV RNA was shown to transiently co-localize with SC35 in nuclear speckles, and SC35 was reported to be binding HDV RNA during active transcription by RNAP II (Bichko & Taylor, 1996; Abrahem & Pelchat, 2008). It is thus possible that SC35 might have a role in HDV RNA transcription. The interaction of HDV RNA with these proteins might also give clues to HDV pathogenesis. Dysregulation of the splicing pathways have been associated with cell transformation and tumorogenesis (Castiglioni et al., 2006; Lee et al., 2006; Pospisil et al., 2006). ASF/SF2 is also involved in the maintenance of genome integrity. It was reported that stable RNA-DNA hybrids (R-loops), that form between nascent RNA transcripts and template DNA, accumulate in ASF/SF2-depleted cells (Li & Manley, 2005; Li et al., 2005). Although not tested, it is possible that under high HDV RNA accumulation, ASF/SF2 might be diverted from protecting chromosomal DNA, which in turn could lead to accumulation of R-loops, ultimately leading to genomic instability, a characteristic of almost all human cancers.
Two additional host proteins known to be involved in splicing were also found to bind HDV RNA: PSF and p54nrb (Greco-Stewart et al., 2006; Sikora et al., 2009). PSF is a multifunctional protein involved in many processes such as splicing, polyadenylation, transcriptional regulation, retention of defective RNAs, nucleic acid unwinding and annealing, nuclear shuttling, and pH homeostasis (Shav-Tal & Zipori, 2002). P54nrb is related to PSF, and both proteins share homology within their C-terminal portions (Dong et al., 1993). PSF forms a heterotetramer with p54nrb, and together they were shown to interact with the C-terminal domain (CTD) of RNAP II during both transcription initiation and elongation (Emili et al., 2002). It is also suggested that PSF might be able to interact with RNA and the CTD of RNAP II simultaneously (Emili et al., 2002). Using co-immunoprecipitations and electrophoretic mobility shift assays of a series of HDV-derived RNAs with purified, recombinant hexahistidine-tagged PSF, it was determined that PSF binds directly to terminal stem-loop domains of both polarities of HDV RNA at locations corresponding to the regions bound by RNAP II (Greco-Stewart et al., 2006), including a section of the HDV RNA genome reported to have RNA promoter activity (Beard et al., 1996; Abrahem & Pelchat, 2008). Recent results indicate that RNAP II interaction with HDV RNA might require both the PSF-HDV RNA interaction and the RNAP II-PSF interaction (Greco-Stewart and Pelchat, unpublished data). This suggests that PSF might provide a direct physical link between HDV RNA and RNAP II to promote initial binding of RNAP II and subsequent transcription on an HDV RNA template. The interaction of PSF with HDV RNA might also provide a mechanism for HDV pathogenesis. PSF mutations have been identified in both cervical cancer and papillary renal carcinoma cell lineages, and PSF dysregulation is associated with induction of several oncogenes (Clark et al., 1997; Benn et al., 2000; Song et al., 2004; Song et al., 2005; Li et al., 2009; Wang et al., 2009). More importantly, it was shown that noncoding RNAs can bind PSF and reverse PSF-mediated repression of several proto-oncogenes, thus promoting cell proliferation and oncogenesis (Song et al., 2004; Song et al., 2005). Thus, it is possible that the interaction of PSF with HDV RNA can reverse PSF repression and promote liver tumor development.
GAPDH was found to bind to the extremities of both polarities of the HDV RNA genome (Lin et al., 2000; Sikora et al., 2009). GAPDH is an enzyme historically known to be involved in glycolysis. In addition to this metabolic role, GAPDH is a multifunctional protein involved in apoptotic cell death, DNA proofreading, nuclear fusion, telomere maintenance, nuclear translocation, cell entry into S-phase, and hyperglycemic stress (Sirover, 2005). GAPDH might also be involved in transcriptional regulation, as it associates with Schizosaccharomyces pombe RNAP II (Mitsuzawa et al., 2005), stimulates RNAP II transcription in Xenopus laevis oocyte (Morgenegg et al., 1986), and was reported to transcriptionally activate histone H2B (Zheng et al., 2003). Although the precise function of GAPDH in HDV biology is still unknown, this protein was reported to facilitate the shuttling of HDV RNA to the nucleus, and to act as a molecular chaperone enhancing
Recently, the eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) was reported to interact with both polarities of the HDV RNA genome (Sikora et al., 2009). eEF1A1 is mostly known for its role in translation where it binds and delivers aminoacyl-tRNA to the ribosome (Brands et al., 1986). Interestingly, eEF1A1 is one of the protein repetitively reported to be involved in viral RNA synthesis. eEF1A1 associates and enhances the RNA-dependent RNA polymerase activities of poliovirus, vesicular stomatitis virus, turnip yellow mosaic virus, and West Nile virus (Joshi et al., 1986; Harris et al., 1994; Blackwell & Brinton, 1997; Das et al., 1998). eEF1A1 has also been reported to be involved in the recruitment of HIV RNA to RNAP II using the HIV TAR element (Wu-Baer et al., 1996). More importantly, eEF1A1 was recently shown to interact with the peach latent mosaic viroid (Dube et al., 2009). Viroids are RNA pathogens very similar to HDV, because they have no replicase and have to rely heavily on their hosts. They are a small, single-stranded, circular RNA pathogens able to infect plants and do not encode any proteins (Flores et al., 2011). Although the function for eEF1A1 interaction with HDV RNA is still unknown, based on its involvement in viral RNA synthesis, it is tempting to speculate that this protein might enhance the RNAP II-mediated replication of HDV RNA. Interaction of HDV RNA with eEF1A1 might also give clues to HDV pathology. In addition to its main role in cellular translation through the binding of tRNAs (Brands et al., 1986), eEF1A1 also binds other highly-structured single-stranded RNA, such as the non-coding RNA HSR1. The eEF1A1-HSR1 complex activates the heat shock transcription factor 1 (HSF1), which binds to DNA elements and induces the expression of heat shock proteins. Although not studied, it is possible that HDV RNA might compete with HSR1 for eEF1A1 binding and block a heat shock response. In agreement with this hypothesis, hsp105, which belongs to the heat shock protein 70 family which is regulated by HSF1, was found to be downregulated in Huh7 cells expressing HDV mRNA (Mota et al., 2008).
5. Conclusion
The mechanisms by which HDV infection contributes to clinical hepatitis are poorly understood. HDV is unique among human viral pathogens in that it has a very limited coding capacity and must rely heavily on host proteins for its life cycle. Over the last few years, several host proteins have been shown to interact with either HDAgs or HDV RNA. Similar to what is observed for other RNA viruses, normal cellular components associated with RNA-processing pathways appear to be exploited by HDV. However, it is likely that several of these proteins interact indirectly with the HDV components, either through host RNA or protein interaction.
Although the normal functions of these proteins are frequently linked to viral replication and/or transcription, their precise roles in both HDV biology and HDV-mediated pathogenesis still need to be clarified. However, their interaction with the HDV RNA genome is consistent with their known biological properties. Several of these proteins are very abundant and are often referred as housekeeping proteins. Nonetheless, it is possible that the high level of HDV RNA occurring during infection could divert some of these proteins from their normal cellular functions, and produce ill effects. Further investigation on these interactions is needed in order to improve our understanding of the mechanisms of both HDV replication and pathogenesis.
Acknowledgments
This work was funded by a Canadian Institutes of Health Research grant to M.P.
References
- 1.
Abrahem A. Pelchat M. 2008 , Nucleic Acids Res.36 5201 5211 - 2.
Beard M. R. Mac Naughton. T. B. Gowans E. J. 1996 , J. Virol.70 4986 4995 - 3.
Benn D. E. Dwight T. Richardson A. L. Delbridge L. Bambach C. P. Stowasser M. Gordon R. D. Marsh D. J. Robinson B. G. 2000 , Cancer Res.60 7048 7051 - 4.
Bichko V. V. Taylor J. M. 1996 , J. Virol.70 8064 8070 - 5.
Blackwell J. L. Brinton M. A. 1997 , J. Virol.71 6433 6444 - 6.
Brands J. H. Maassen J. A. van Hemert F. J. Amons R. Moller W. 1986 The primary structure of the alpha subunit of human elongation factor 1. Structural aspects of guanine-nucleotide-binding sites, Eur. J. Biochem.155 167 171 - 7.
Brazas R. Ganem D. 1996 , Science274 90 94 - 8.
Cao D. Haussecker D. Huang Y. Kay M. A. 2009 , RNA15 1971 1979 - 9.
Casey J. L. Bergmann K. F. Brown T. L. Gerin J. L. 1992 , Proc. Natl. Acad. Sci. USA89 7149 7153 - 10.
Casey J. L. Gerin J. L. 1995 , J. Virol.69 7593 7600 - 11.
Castiglioni F. Tagliabue E. Campiglio M. Pupa S. M. Balsari A. Menard S. 2006 , Endocr Relat Cancer13 221 232 - 12.
Chang F. L. Chen P. J. Tu S. J. Wang C. J. Chen D. S. 1991 , Proc. Natl. Acad. Sci. USA88 8490 8494 - 13.
Chang J. Gudima S. O. Tarn C. Nie X. Taylor J. M. 2005 , J Virol79 8182 8188 - 14.
Chang J. Gudima S. O. Taylor J. M. 2005 , J Virol79 13310 13316 - 15.
Chang J. Nie X. Chang H. E. Han Z. Taylor J. 2008 , J. Virol.82 1118 1127 - 16.
Chang M. F. Baker S. C. Soe L. H. Kamahora T. Keck J. G. Makino S. Govindarajan S. Lai M. M. 1988 , J. Virol.62 2403 2410 - 17.
Chao M. Hsieh S. Y. Taylor J. 1990 , J. Virol.64 5066 5069 - 18.
Chen P. J. Kalpana G. Goldberg J. Mason W. Werner B. Gerin J. Taylor J. 1986 , Proc. Natl. Acad. Sci. USA83 8774 8778 - 19.
Clark J. Lu Y. J. Sidhar S. K. Parker C. Gill S. Smedley D. Hamoudi R. Linehan W. M. Shipley J. Cooper C. S. 1997 Fusion of splicing factor genes PSF and NonO (54nrb to the TFE3 gene in papillary renal cell carcinoma, Oncogene 15, 2233-2239 - 20.
Cole S. M. Gowans E. J. Macnaughton T. B. Hall P. D. Burrell C. J. 1991 , Hepatology13 845 851 - 21.
Cole S. M. Macnaughton T. B. Gowans E. J. 1993 Differential roles for HDAg-24 and-p27 in HDV pathogenesis, Prog Clin Biol Res 382, 131-138 - 22.
Das T. Mathur M. Gupta A. K. Janssen G. M. Banerjee A. K. 1998 , Proc. Natl. Acad. Sci. USA95 1449 1454 - 23.
De B. P. Gupta S. Zhao H. Drazba J. A. Banerjee A. K. 1996 , J Biol Chem271 24728 24735 - 24.
de la Cruz J. Kressler D. Linder P. 1999 , Trends Biochem Sci24 192 198 - 25.
Dong B. Horowitz D. S. Kobayashi R. Krainer A. R. 1993 Purification and cDNA cloning of HeLa cell54nrb a nuclear protein with two RNA recognition motifs and extensive homology to human splicing factor PSF and Drosophila NONA/BJ6, Nucleic Acids Res. 21, 4085-4092 - 26.
Dube A. Bisaillon M. Perreault J. P. 2009 , Journal of Virology83 12057 12067 - 27.
Emili A. Shales M. Mc Cracken S. Xie W. Tucker P. W. Kobayashi R. Blencowe B. J. Ingles C. J. 2002 Splicing and transcription-associated proteins PSF and54nrb nonO bind to the RNA polymerase II CTD, RNA 8, 1102-1111 - 28.
Farci P. Karayiannis P. Lai M. E. Marongiu F. Orgiana G. Balestrieri A. Thomas H. C. 1988 , J Med Virol26 279 288 - 29.
Fattovich G. Stroffolini T. Zagni I. Donato F. 2004 , Gastroenterology 127, S35 50 - 30.
Filipovska J. Konarska M. M. 2000 , RNA6 41 54 - 31.
Flores R. Grubb D. Elleuch A. Nohales M. A. Delgado S. Gago S. 2011 , RNA Biol 8, - 32.
Fu T. B. Taylor J. 1993 , J. Virol.67 6965 6972 - 33.
Ghisolfi L. Joseph G. Amalric F. Erard M. 1992 , J. Biol. Chem.267 2955 2959 - 34.
Glenn J. S. Watson J. A. Havel C. M. White J. M. 1992 , Science256 1331 1333 - 35.
Goto T. Kato N. Ono-Nita S. K. Yoshida H. Otsuka M. Shiratori Y. Omata M. 2000 , J. Biol. Chem.275 37311 37316 - 36.
Goto T. Kato N. Yoshida H. Otsuka M. Moriyama M. Shiratori Y. Koike K. Matsumura M. Omata M. 2003 , J. Infect. Dis.187 820 828 - 37.
Greco-Stewart V. S. Miron P. Abrahem A. Pelchat M. 2007 , Virology357 68 78 - 38.
Greco-Stewart V. S. Pelchat M. 2010 , Viruses2 189 212 - 39.
Greco-Stewart V. S. Schissel E. Pelchat M. 2009 , Virology386 12 15 - 40.
Greco-Stewart V. S. Thibault C. S. Pelchat M. 2006 , Virology356 35 44 - 41.
Gudima S. Dingle K. Wu T. T. Moraleda G. Taylor J. 1999 , J Virol73 6533 6539 - 42.
Gudima S. Wu S. Y. Chiang C. M. Moraleda G. Taylor J. 2000 , J. Virol.74 7204 7210 - 43.
Han Z. Alves C. Gudima S. Taylor J. 2009 , J. Virol.83 6457 6463 - 44.
Harris K. S. Xiang W. Alexander L. Lane W. S. Paul A. V. Wimmer E. 1994 , J. Biol. Chem.269 27004 27014 - 45.
Hastings M. L. Krainer A. R. 2001 , Curr Opin Cell Biol13 302 309 - 46.
Haussecker D. Cao D. Huang Y. Parameswaran P. Fire A. Z. Kay M. A. 2008 , Nat. Struct. Mol. Biol.15 714 721 - 47.
Hiscox J. A. 2002 , Arch. Virol.147 1077 1089 - 48.
Huang W. H. Yung B. Y. Syu W. J. Lee Y. H. 2001 , J. Biol. Chem.276 25166 25175 - 49.
Huang Y. Steitz J. A. 2001 , Mol Cell7 899 905 - 50.
Joshi R. L. Ravel J. M. Haenni A. L. 1986 , EMBO J.5 1143 1148 - 51.
Krogsgaard K. Kryger P. Aldershvile J. Andersson P. Sorensen T. I. Nielsen J. O. 1987 , Hepatology7 42 45 - 52.
Kuo M. Y. Chao M. Taylor J. 1989 , J. Virol.63 1945 1950 - 53.
Kuo M. Y. Goldberg J. Coates L. Mason W. Gerin J. Taylor J. 1988 , J. Virol.62 1855 1861 - 54.
Lai M. M. 1998 , Virology244 1 12 - 55.
Lai M. M. 2005 , J. Virol.79 7951 7958 - 56.
Lee C. H. Chang S. C. Chen C. J. Chang M. F. 1998 , J. Biol. Chem.273 7650 7656 - 57.
Lee C. Z. Chen P. J. Chen D. S. 1995 , J. Virol.69 5332 5336 - 58.
Lee E. J. Jo M. Park J. Zhang W. Lee J. H. 2006 , Biochem Biophys Res Commun347 882 888 - 59.
Lehmann E. Brueckner F. Cramer P. 2007 , Nature450 445 449 - 60.
Li L. Feng T. Lian Y. Zhang G. Garen A. Song X. 2009 , Proc. Natl. Acad. Sci. USA106 12956 12961 - 61.
Li X. Manley J. L. 2005 , Cell122 365 378 - 62.
Li X. Wang J. Manley J. L. 2005 , Genes Dev19 2705 2714 - 63.
Li Y. J. Macnaughton T. Gao L. Lai M. M. 2006 , J. Virol.80 6478 6486 - 64.
Li Y. J. Stallcup M. R. Lai M. M. 2004 , J. Virol.78 13325 13334 - 65.
Lin S. S. Chang S. C. Wang Y. H. Sun C. Y. Chang M. F. 2000 , Virology271 46 57 - 66.
Liu X. Mertz J. E. 1995 , Genes Dev9 1766 1780 - 67.
Lo K. Sheu G. T. Lai M. M. 1998 , Virology247 178 188 - 68.
Mac Naughton. T. B. Gowans E. J. Mc Namara S. P. Burrell C. J. 1991 , Virology184 387 390 - 69.
Macnaughton T. B. Shi S. T. Modahl L. E. Lai M. M. 2002 , J. Virol.76 3920 3927 - 70.
Mitsuzawa H. Kimura M. Kanda E. Ishihama A. 2005 , FEBS Lett579 48 52 - 71.
Modahl L. E. Macnaughton T. B. Zhu N. Johnson D. L. Lai M. M. 2000 , Mol. Cell. Biol.20 6030 6039 - 72.
Moraleda G. Taylor J. 2001 , J Virol75 10161 10169 - 73.
Morgenegg G. Winkler G. C. Hubscher U. Heizmann C. W. Mous J. Kuenzle C. C. 1986 , J Neurochem47 54 62 - 74.
Mota S. Mendes M. Freitas N. Penque D. Coelho A. V. Cunha C. 2009 , J Proteomics72 616 627 - 75.
Mota S. Mendes M. Penque D. Coelho A. V. Cunha C. 2008 , J. Proteomics71 71 79 - 76.
Mu J. J. Chen D. S. Chen P. J. 2001 , J. Virol.75 9087 9095 - 77.
Mu J. J. Tsay Y. G. Juan L. J. Fu T. F. Huang W. H. Chen D. S. Chen P. J. 2004 , Virology319 60 70 - 78.
Mu J. J. Wu H. L. Chiang B. L. Chang R. P. Chen D. S. Chen P. J. 1999 , J. Virol.73 10540 10545 - 79.
Niranjanakumari S. Lasda E. Brazas R. Garcia-Blanco M. A. 2002 , Methods26 182 190 - 80.
Okuwaki M. 2008 , J. Biochem.143 441 448 - 81.
Otto J. C. Casey P. J. 1996 , J. Biol. Chem.271 4569 4572 - 82.
Pascarella S. Negro F. 2011 , Liver Int31 7 21 - 83.
Polson A. G. Ley H. L. 3rd Bass B. L. Casey J. L. 1998 , Mol. Cell. Biol.18 1919 1926 - 84.
Pospisil H. Herrmann A. Butherus K. Pirson S. Reich J. G. Kemmner W. 2006 , BMC Genomics 7, 148 - 85.
Rizzetto M. Canese M. G. Arico S. Crivelli O. Trepo C. Bonino F. Verme G. 1977 , Gut18 997 1003 - 86.
Romeo R. Del Ninno E. Rumi M. Russo A. Sangiovanni A. de Franchis R. Ronchi G. Colombo M. 2009 A28 year Study of the Course of Hepatitis Delta Infection, a Risk Factor for Cirrhosis and Hepatocellular Carcinoma, Gastroenterology - 87.
Ryu W. S. Bayer M. Taylor J. 1992 , J. Virol.66 2310 2315 - 88.
Ryu W. S. Netter H. J. Bayer M. Taylor J. 1993 , J. Virol.67 3281 3287 - 89.
Schultz D. E. Hardin C. C. Lemon S. M. 1996 , J Biol Chem271 14134 14142 - 90.
Shav-Tal Y. Zipori D. 2002 PSF and54 nrb)/NonO--multi-functional nuclear proteins, FEBS Lett. 531, 109-114 - 91.
Sikora D. Greco-Stewart V. S. Miron P. Pelchat M. 2009 The hepatitis delta virus RNA genome interacts with eEF1A1,54 nrb), hnRNP-L, GAPDH and ASF/SF2, Virology 390, 71-78 - 92.
Sirover M. A. 2005 , J. Cell. Biochem.95 45 52 - 93.
Song X. Sui A. Garen A. 2004 , Proc Natl Acad Sci U S A101 621 626 - 94.
Song X. Sun Y. Garen A. 2005 , Proc Natl Acad Sci U S A102 12189 12193 - 95.
Su C. W. Huang Y. H. Huo T. I. Shih H. H. Sheen I. J. Chen S. W. Lee P. C. Lee S. D. Wu J. C. 2006 , Gastroenterology130 1625 1635 - 96.
Sureau C. Moriarty A. M. Thornton G. B. Lanford R. E. 1992 , J. Virol.66 1241 1245 - 97.
Taylor J. M. 2006 , Virology344 71 76 - 98.
Taylor J. M. 2009 , Adv. Virus Res.74 103 121 - 99.
Tseng C. H. Lai M. C. 2009 , Viruses1 818 831 - 100.
Tuteja R. Tuteja N. 1998 , Crit. Rev. Biochem. Mol. Biol.33 407 436 - 101.
Wang C. C. Chang T. C. Lin C. W. Tsui H. L. Chu P. B. Chen B. S. Huang Z. S. Wu H. N. 2003 , Nucleic Acids Res.31 6481 6492 - 102.
Wang D. Pearlberg J. Liu Y. T. Ganem D. 2001 , J Virol75 3600 3604 - 103.
Wang G. Cui Y. Zhang G. Garen A. Song X. 2009 , Proc. Natl. Acad. Sci. USA106 16794 16798 - 104.
Wei Y. Ganem D. 1998 , J. Virol.72 2089 2096 - 105.
Weiner A. J. Choo Q. L. Wang K. S. Govindarajan S. Redeker A. G. Gerin J. L. Houghton M. 1988 A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides24 delta and p27 delta, J. Virol. 62, 594-599 - 106.
Wen X. Tannukit S. Paine M. L. 2008 , Int J Mol Sci9 2105 2113 - 107.
Wong S. K. Lazinski D. W. 2002 , Proc. Natl. Acad. Sci. USA99 15118 15123 - 108.
Wu-Baer F. Lane W. S. Gaynor R. B. 1996 , J. Biol. Chem.271 4201 4208 - 109.
Yamaguchi Y. Filipovska J. Yano K. Furuya A. Inukai N. Narita T. Wada T. Sugimoto S. Konarska M. M. Handa H. 2001 , Science293 124 127 - 110.
Yamaguchi Y. Mura T. Chanarat S. Okamoto S. Handa H. 2007 , Genes Cells12 863 875 - 111.
Yudkovsky N. Ranish J. A. Hahn S. 2000 , Nature408 225 229 - 112.
Zheng L. Roeder R. G. Luo Y. 2003 , Cell114 255 266